Horizon Discovery and RIKEN GENESIS Sign Distribution Agreement
News Jul 16, 2013
Horizon Diagnostics has announced that it has signed a distribution agreement with RIKEN GENESIS, to become sole distributor of HDx’s molecular reference standards in Japan.
RIKEN GENESIS offers cutting-edge genomic products and services to a wide range of research institutions and corporations, and is a CAP (College of American Pathologists) accredited laboratory for genome analysis services.
Reliable and renewable sources of reference standards are essential for molecular laboratories; however a lack of availability has previously been a major obstacle.
Even when patient samples are available, variability in DNA extraction and a lack of standardization have proven to be additional serious sources of error.
Horizon’s HDx division has developed reliable and renewable genetically defined and thoroughly validated reference materials, providing an industry standard for the development of and quality control of molecular assays, thereby directly improving their accuracy.
Horizon’s Molecular Reference Standards include FFPE cell line blocks and purified gDNA. In early 2013 HDx launched its first Quantitative Multiplex DNA Reference Standard, intended for researchers assessing multiple biomarkers in a single assay, using platforms such as next generation sequencing (NGS).
“Part of our mission at RIKEN GENESIS is to contribute to translating the results of genetic research into clinical settings,” said Yusuke Tsukahara, President and CEO, RIKEN GENESIS.
Tsukahara continued, “Horizon’s Molecular Reference Standards are a valuable step in the move towards practical implementation of personalized medicine, and we are delighted to be working with such a forward looking company.”
“At the cutting edge of genome analysis, RIKEN GENESIS is an ideal partner for Horizon. We aim to affiliate ourselves with the best, like-minded companies for distribution; those dedicated to customer service, cutting edge science and ultimately better patient care,” commented Dr Brian Burke, Business Development Manager, Horizon Diagnostics. “We look forward to working with the team to develop the molecular reference standards market in Japan.”
New Approach Identifies Important Undiscovered Functions of ProteinsNews
Scientists have developed a new method to discover which surface contacts on proteins are critical for these cellular interactions. The novel approach shows that essential new functions can be uncovered even for well-studied proteins, and has significant implications for therapeutic drug development, which depends heavily on how drugs physically interact with their cellular targets.READ MORE
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE